4-[(2-氯-6-氟苄基)氧基]苯甲醛 | 172932-10-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 4-[(2-氯-6-氟苄基)氧基]苯甲醛
• 中文别名: 4-(2-氯-6-氟-苄基)氧基苯甲醛；4-[(2-氯-6-氟苯基)甲氧基]苯甲醛
• 英文名称: 4-[(2-chloro-6-fluorophenyl)methoxy]benzaldehyde
• 英文别名: 4-(2-chloro-6-fluorobenzyloxy)benzaldehyde
• CAS: 172932-10-4
• 化学式: C₁₄H₁₀ClFO₂
• mdl: MFCD00052227
• 分子量: 264.684
• InChiKey: WOUZCDNRKXWPDY-UHFFFAOYSA-N

物化性质

• 熔点：
  80-82°C
• 沸点：
  388.8±32.0 °C(Predicted)
• 密度：
  1.310±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S24/25,S26,S36
• 危险类别码：
  R36/37/38
• 海关编码：
  2913000090

SDS

Name:	4-[(2-Chloro-6-fluorobenzyl)oxy]benzaldehyde 97% Material Safety Data Sheet
Synonym:
CAS:	172932-10-4

Section 1 - Chemical Product MSDS Name:4-[(2-Chloro-6-fluorobenzyl)oxy]benzaldehyde 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
172932-10-4	4-[(2-Chloro-6-fluorobenzyl)oxy]benzal	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 172932-10-4: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: pale orange - white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 78 - 80 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C14H10ClFO2
Molecular Weight: 264.68

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, carbon monoxide, carbon dioxide, hydrogen fluoride gas, fluorine.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 172932-10-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-[(2-Chloro-6-fluorobenzyl)oxy]benzaldehyde - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 172932-10-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 172932-10-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 172932-10-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-[(2-氯-6-氟苄基)氧基]苯甲醛 在 nickel(II) tetrafluoroborate hexahydrate 、 氨 、 氢气 、 双(2-二苯基膦乙基)苯基磷 作用下， 以 2,2,2-三氟乙醇 为溶剂， 反应 24.0h， 以82%的产率得到[4-[(2-Chloro-6-fluorophenyl)methoxy]phenyl]methanamine
  参考文献：
  名称：

  使用镍基均相催化剂的通用和选择性合成伯胺

  摘要：

  通过应用丰富且原子经济的试剂来开发用于工业上相关的胺化和氢化反应的贱金属催化剂，对于经济高效且可持续地合成代表非常重要的化学物质的胺而言，仍然至关重要。尤其是，伯胺的合成至关重要，因为这些化合物用作生产增值精细化学品和散装化学品以及药品，农用化学品和原料的关键前体和主要中间体。在这里，我们报道了一种Ni-triphos络合物，它是第一个用于镍的羰基化合物与氨的还原胺化和硝基芳烃加氢制备各种伯胺的Ni基均相催化剂。值得注意的是，这种镍配合物可以合成功能化且结构多样的苄基，杂环和脂肪族直链和支链伯胺以及芳香族伯胺，是使用氨和分子氢从廉价且易于获得的羰基化合物（醛和酮）和硝基芳烃开始的。这种镍催化的还原胺化方法已用于胺化更复杂的药物和类固醇衍生物。已经对基于Ni-triphos的还原胺化反应进行了详细的DFT计算，结果表明整个反应具有H的内球机理。这种镍催化的还原胺化方法已用于胺化更复杂的药物和

  DOI：

  10.1039/d0sc01084g

文献信息

• Structure−Activity Relationship Study of Prion Inhibition by 2-Aminopyridine-3,5-dicarbonitrile-Based Compounds:  Parallel Synthesis, Bioactivity, and in Vitro Pharmacokinetics
  作者：Barnaby C. H. May、Julie A. Zorn、Juanita Witkop、John Sherrill、Andrew C. Wallace、Giuseppe Legname、Stanley B. Prusiner、Fred E. Cohen

  DOI：10.1021/jm061045z

  日期：2007.1.1

  2-Aminopyridine-3,5-dicarbonitrile compounds were previously identified as mimetics of dominant-negative prion protein mutants and inhibit prion replication in cultured cells. Here, we report findings from a comprehensive structure-activity relationship study of the 6-aminopyridine-3,5-dicarbonitrile scaffold. We identify compounds with significantly improved bioactivity (approximately 40-fold) against

  2-氨基吡啶-3,5-二甲腈化合物以前被鉴定为显性负病毒蛋白突变体的模拟物，并抑制病毒在培养细胞中的复制。在这里，我们报告从6-氨基吡啶-3,5-二甲腈支架的全面的结构-活性关系研究中发现的结果。我们确定了具有明显改善的生物活性（约40倍）的抗感染性ion病毒同工型（PrPSc）复制和合适的药代动力学特征的化合物，以保证在病毒疾病的动物模型中进行评估。
• [EN] AGONISTS AND ANTAGONISTS OF THE S1P5 RECEPTOR, AND METHODS OF USES THEREOF<br/>[FR] AGONISTES ET ANTAGONISTES DU RÉCEPTEUR S1P5, ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ABBOTT LAB

  公开号：WO2010093704A1

  公开（公告）日：2010-08-19

  Disclosed are compounds that are agonists or antagonists of the S1P5 receptor, compositions comprising said compounds, and methods of using said compounds and compositions. In certain embodiments, said compounds are 1-benzylazetidine-3-carboxylic acid derivatives. In certain embodiments, said methods relate to the treatment of neuropatic pain and/or a neurodegenerative disorder. In certain embodiments, said compounds may be used in combination with a second therapeutic agent.

  本文披露了作为S1P5受体激动剂或拮抗剂的化合物，包括含有这些化合物的组合物，以及使用这些化合物和组合物的方法。在某些实施例中，这些化合物是1-苄基氮杂环丙氨酸衍生物。在某些实施例中，这些方法涉及治疗神经痛和/或神经退行性疾病。在某些实施例中，这些化合物可以与第二治疗剂结合使用。
• [EN] SUBSTITUTED ISOXAZOLE AMIDE COMPOUNDS AS INHIBITORS OF STEAROYL-COA DESATURASE 1 (SCD1)<br/>[FR] COMPOSÉS D'AMIDE D'ISOXAZOLE SUBSTITUÉS EN TANT QU'INHIBITEURS DE STÉAROYL-COA DÉSATURASE 1 (SCD1)
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014086704A1

  公开（公告）日：2014-06-12

  The invention is concerned with a compound of formula (I) and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and using the compound of formula (I) as well as pharmaceutical compositions containing such compounds. The compound of formula (I) are SCD1 inhibitors and may be useful in treating cancer.

  该发明涉及一种具有化学式(I)及其药学上可接受的盐的化合物。此外，本发明涉及制造和使用化学式(I)化合物的方法，以及含有这种化合物的药物组合物。化学式(I)的化合物是SCD1抑制剂，可能在治疗癌症方面有用。
• Marine natural products-inspired phenylmethylene hydantoins with potent in vitro and in vivo antitumor activities via suppression of Brk and FAK signaling
  作者：Asmaa A. Sallam、Mohamed M. Mohyeldin、Ahmed I. Foudah、Mohamed R. Akl、Sami Nazzal、Sharon A. Meyer、Yong-Yu Liu、Khalid A. El Sayed

  DOI：10.1039/c4ob00553h

  日期：——

  The synthetic marine-inspired PMH analog 7 showed promising in vitro and in vivo antitumor effects against breast cancer via targeting Brk and FAK signaling pathways.

  合成的海洋灵感PMH类似物7显示出有希望的体外和体内抗乳腺癌效果，通过靶向Brk和FAK信号通路。
• Usnic Acid Benzylidene Analogues as Potent Mechanistic Target of Rapamycin Inhibitors for the Control of Breast Malignancies
  作者：Hassan Y. Ebrahim、Mohamed R. Akl、Heba E. Elsayed、Ronald A. Hill、Khalid A. El Sayed

  DOI：10.1021/acs.jnatprod.6b00917

  日期：2017.4.28

  benzylidene analogues of 1 displayed excellent fitting into a targeted deep hydrophobic pocket at the core of the kinase cleft, through stacking with the phenolic side chain of the Tyr2225 residue. Several potent analogues were generated, including 52, that exhibited potent (nM concentrations) antiproliferative, antimigratory, and anti-invasive activities against cells from multiple breast cancer clonal

  （+）-松果酸（1）是具有特征性的二苯并呋喃支架的常见的生物活性的地衣来源的次级代谢产物。它显示出较低的微摩尔抗增殖活性水平，尤其是在一组多种乳腺癌细胞系中诱导自噬，提示雷帕霉素（mTOR）的机制靶标（以前为“哺乳动物”）是潜在的大分子靶标。由于抑制mTOR下游效应子，细胞自噬标志物显着上调。另外，1显示了在mTOR激酶口袋处的最佳结合姿势，这是通过与关键氨基酸的多次相互作用而实现的。合理设计的1的亚苄基类似物通过与Tyr2225残基的酚侧链堆叠，可以很好地拟合激酶缝隙核心的目标深疏水口袋。产生了几种有效的类似物，包括52种，对来自多个乳腺癌克隆系的细胞表现出有效的（nM浓度）抗增殖，抗迁移和抗侵袭活性，而不会影响非致瘤性MCF-10A乳腺上皮细胞。类似物52还表现出有效的mTOR抑制和自噬诱导作用。再说52在两只无胸腺裸鼠乳腺癌异种移植模型中显示出有效的体内抗肿瘤活性。总的来说，松萝酸和